先天性瘦素缺乏的分类
该研究通过系统文献检索、本中心患者未发表数据及体外分析,对148例患者中28种纯合瘦素基因变异进行系统分类,分为经典激素缺乏、生物活性失活激素和拮抗性激素3种亚型,并分析亚型与临床表型严重程度及治疗反应的相关性。
要点
- 先天性瘦素缺乏可分为经典激素缺乏、生物活性失活激素和拮抗性激素3种亚型。
- 生物活性失活激素亚型患者95百分位体重指数百分比较高。
- 经典激素缺乏和生物活性失活激素亚型可用相同起始剂量美曲普汀治疗,拮抗性激素亚型需根据变异调整治疗。
核心结论
- 基于分子和功能特征对瘦素变异进行分类,有助于确定先天性瘦素缺乏患者最合适的治疗方法。
研究设计与样本
- 系统文献研究,补充本中心患者未发表数据及新的体外分析,共纳入148例患者,鉴定出28种不同的纯合瘦素变异。
主要发现
- 28种纯合瘦素变异分为3种亚型:经典激素缺乏(21种变异,128例患者)、生物活性失活激素(3种变异,12例患者)、拮抗性激素(3种变异,7例患者);仅1种变异(1例患者)未分类。
- 生物活性失活激素患者95百分位体重指数百分比较经典激素缺乏患者更高。
- 经典激素缺乏和生物活性失活激素患者可采用相同起始剂量的美曲普汀治疗,拮抗性激素患者需要根据变异调整治疗方案以克服变异瘦素的拮抗特性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Biallelic pathogenic leptin gene variants cause severe early-onset obesity usually associated with low or undetectable circulating leptin levels. Recently, variants have been described resulting in secreted mutant forms of the hormone leptin with either biologically inactive or antagonistic properties. METHODS: We conducted a systematic literature research supplemented by unpublished data from patients at our center as well as new in vitro analyses to provide a systematic classification of congenital leptin deficiency based on the molecular and functional characteristics of the underlying leptin variants and investigated the correlation of disease subtype with severity of the clinical phenotype. RESULTS: A total of 28 distinct homozygous leptin variants were identified in 148 patients. The identified variants can be divided into 3 different subtypes of congenital leptin deficiency: classical hormone deficiency (21 variants in 128 patients), biologically inactive hormone (3 variants in 12 patients), and antagonistic hormone (3 variants in 7 patients). Only 1 variant (n = 1 patient) remained unclassified. Patients with biological inactive leptin have a higher percentage of 95th body mass index percentile compared to patients with classical hormone deficiency. While patients with both classical hormone deficiency and biological inactive hormone can be treated with the same starting dose of metreleptin, patients with antagonistic hormone need a variant-tailored treatment approach to overcome the antagonistic properties of the variant leptin. MAIN CONCLUSION: Categorization of leptin variants based on molecular and functional characteristics helps to determine the most adequate approach to treatment of patients with congenital leptin deficiency.
引用
- von Schnurbein J, Zorn S, Nunziata A, et al. Classification of Congenital Leptin Deficiency. J Clin Endocrinol Metab. 2024. PMID: 38470203. doi:10.1210/clinem/dgae149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。